PCRX Stock — Pacira BioSciences, Inc.

Pacira BioSciences, Inc. (PCRX)

Updated October 16, 2026.

PCRX is a Stock. Total return is 417.7% over the past 15.7 years, 251.2 points behind SPY at 668.9%.

Pacira BioSciences develops and commercializes non-opioid pain management and regenerative health solutions, including injectable suspensions like EXPAREL for postsurgical pain and ZILRETTA for osteoarthritis, as well as the iovera cryoanalgesia device and a gene therapy platform in development. The company does not currently have an established distribution to shareholders. This operating pharmaceutical company appeals to investors seeking exposure to specialty pain management therapeutics rather than dividend income.

PCRX performance versus SPY

Price and return data through 2026-10-16.

Total return is 417.7% over the past 15.7 years, 251.2 points behind SPY at 668.9%. Over the past year its total return — price change plus distributions reinvested — is 59.6%. Its deepest 1-year drawdown was 28.2%.

PCRX key facts

Asset type

Stock

Asset class

Equity

Inception date

02/03/2011

Distribution frequency

None

Last close

$36.34 (as of 2026-10-16)

Market cap

$1,450,410,293

Average volume

960886.0

Beta

0.252

Payout ratio

0.0%

P/E ratio

103.83

Forward P/E

6.25

EPS

$0.35

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

PCRX risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 28.2%.

Who may consider PCRX — and who may not

It is a weaker fit for investors who need monthly cash flow (PCRX does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on PCRX

• All tickers starting with P

Tagged: Pharmaceutical.

Frequently asked questions